Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2579-2594

  Chen, Yijie ^a,b   Wang, Xinran ^c,d   Liu, Ting ^c,d   Zhang, Ding Sheng zi ^a,b   Wang, Yunfei ^c,d   Gu, Hongchen ^a,b   Di, Wen ^c,d  

^a School of Medicine   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Shanghai Key Laboratory of Gynecologic Oncology   (China)

Author keywords

Antiangiogenesis; Mesoporous silica nanoparticles; Ovarian cancer; Small interfering RNA; Vascular endothelial growth factor

Indexed keywords

MACROGOL; NANOCARRIER; POLYETHYLENEIMINE; SILICA NANOPARTICLE; SMALL INTERFERING RNA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MAGNETITE NANOPARTICLE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SIZE; DRUG CAPSULE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; ENDOSOME; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; INTERNALIZATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; VEGF GENE; ANIMAL; CHEMISTRY; GENE THERAPY; GENETICS; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; HUMANS; MAGNETITE NANOPARTICLES; MICE; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84928137606     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S78774     Document Type: Article

References (36)

1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
2. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719-725.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature. 2000;407(6801):249-257.
4. Gavalas NG, Liontos M, Trachana S-P, et al. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci. 2013;14(8):15885-15909.
5. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873-887.
6. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190-3200.
7. Krämer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;(32):1-14.
8. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62(6):707-709.
9. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma - mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132(2):496-505.
10. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer - a time for reappraisal? Eur J Cancer. 2009;45(14):2452-2461.
11. Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051-5060.
12. Liu F, Gao G, Tu K, Yu L, Gao J. Small interfering RNA targeting MDR1 inhibits ovarian cancer growth and increases efficacy of chemotherapy in vivo. Chin J Cancer Res. 2009;21(4):318-324.
13. Fan Y, Xin XY, Chen BL, Ma X. Knockdown of Rab25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 2006;38(6):561-567.
14. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193-6204.
15. Koyanagi T, Suzuki Y, Saga Y, et al. In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci. 2013;104(12):1705-1710.
16. Goldberg MS. siRNA delivery for the treatment of ovarian cancer. Methods. 2013;63(2):95-100.
17. Florinas S, Kim J, Nam K, Janát-Amsbury MM, Kim SW. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release. 2014;183:1-8.
18. Lai C-Y, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc. 2003;125(15):4451-4459.
19. Yang P, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev. 2012;41(9):3679-3698.
20. Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637-3657.
21. Chen Y, Gu H, Zhang DS-Z, Li F, Liu T, Xia W. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35(38):10058-10069.
22. Li X, Zhang J, Gu H. Adsorption and desorption behaviors of DNA with magnetic mesoporous silica nanoparticles. Langmuir. 2011;27(10):6099-6106.
23. Li X, Xie QR, Zhang J, Xia W, Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials. 2011;32(35):9546-9556.
24. Yang X, Du J, Dou S, Mao C, Long H, Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano. 2012;6(1):771-781.
25. Lee H, Jeong JH, Park TG. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J Control Release. 2002;79(1-3):283-291.
26. Min S-H, Kim DM, Kim MN, et al. Gene delivery using a derivative of the protein transduction domain peptide, K-Antp. Biomaterials. 2010;31(7):1858-1864.
27. Wang Y, Liu P, Qiu L, et al. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials. 2013;34(16):4068-4077.
28. Wang Y, Liu P, Duan Y, et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials. 2014;35(3):983-992.
29. Li X, Chen Y, Wang M, Ma Y, Xia W, Gu H. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials. 2013;34(4):1391-1401.
30. Huang H-Y, Kuo W-T, Chou M-J, Huang Y-Y. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A. 2011;97(3):330-338.
31. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials. 2011;32(4):1242-1252.
32. Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-2722.
33. Slowing II, Vivero-Escoto JL, Wu C-W, Lin VS-Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278-1288.
34. Cohen JG, White M, Cruz A, Farias-Eisner R. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem. 2014;5(3):286-300.
35. Bellomo C. A mathematical model of the immersion of a spherical tumor with a necrotic core into a nutrient bath. Math Comput Model. 2006;43(7-8):779-786.
36. Tindall MJ, Please CP, Peddie MJ. Modelling the formation of necrotic regions in avascular tumours. Math Biosci. 2008;211(1):34-55.